Study End Points
bleeding, death, stroke, cardiac death, Thrombosis
BLEEDING, MYOCARDIAL INFARCTION, STROKE, MINOR, CARDIAC DEATH, THROMBOSIS, SECONDARY, EVENTS
There were 2 primary end points in this study. The primary safety end point was a composite of major bleeding, clinically relevant nonmajor bleeding, and minor bleeding events, as defined by the International Society on Thrombosis and Haemostasis (ISTH). The primary efficacy end point was major adverse cardiovascular events (MACEs), a composite end point of cardiac death, myocardial infarction, re-revascularization, or stroke during the 6-month follow-up period. The secondary end points included all-cause death and cardiac-related rehospitalization. Complete definitions of the end points are provided in eAppendix 3 in 